Allergy Therapeutics is writing a story of resilience ... Its August results hinted at a turning point. In the second half of the financial year, the company posted its first revenue growth ...

2024 has been a turning point in the fight against Alzheimer ... with new generation therapeutics recently succeeding in clinical trials to achieve regulatory approval. For the past 30 years ...

The co-developer of a US-approved drug, Professor Andrew Wilks has formed Synthesis Bioventures to sniff out more winners.

TG Therapeutics, Inc. (NASDAQ ... Beyond CF and pain, Vertex has focused its pipeline around genetically driven diseases with the potential for a transformative clinical benefit.

Its pipeline also includes Claudin 18.2-directed ADC BMS-986476 in phase 2 for gastrointestinal and pancreatic cancer, acquired as a result of its acquisition of Turning Point Therapeutics for $4. ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Global Advisors’ managing partner, Tom Lee, shared his thoughts on the potential of small and mid-cap stocks in 2025.

Compared to previously launched biosimilars, these therapeutics are gaining market ... This could be an important turning point for manufacturers, such as Boehringer Ingelheim and Pfizer, that ...

VYNE Therapeutics (VYNE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph ...

Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price ...

Cullinan Therapeutics’ strong financial position funds growth into 2028. Find out why CGEM stock presents a compelling buy ...